{"analyses":[{"ciLowerLimit":"0.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.33","estimateComment":"Cox Proportional Hazard Model (Arm A vs. Arm B) stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Log Rank Test stratified by factors as recorded in IXRS, i.e., presence of del17p (Yes/No), ECOG (0-1/2), # of prior therapies (1-3/4+).","paramType":"Hazard Ratio (HR)","paramValue":"0.23","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Kaplan-Meier estimate of median DOR and upper 95% CI were not reached.","groupId":"OG000","lowerLimit":"41.5","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"11.9","upperLimit":"21.7","value":"18.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"description":"Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Acalabrutinib 100 mg orally twice a day","id":"OG000","title":"Arm A: Acalabrutinib Monotherapy"},{"description":"Idelalisib+Rituximab or Bendamustine + Retuximab","id":"OG001","title":"Arm B: Investigator's Choice"}],"paramType":"MEDIAN","populationDescription":"Intent to treat (ITT) population including all randomized participants","reportingStatus":"POSTED","timeFrame":"Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.","title":"Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff","type":"SECONDARY","unitOfMeasure":"Months"}